Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Fennec Pharmaceuticals ( (TSE:FRX) ) is now available.
Fennec Pharmaceuticals has announced that the University of Arizona Cancer Center will conduct an investigator-sponsored Phase I/II trial of PEDMARK in adolescent, young adult and adult patients with head and neck and testicular cancers receiving cisplatin chemotherapy. The open-label study will evaluate PEDMARK’s ability to reduce cisplatin-induced hearing loss and examine cisplatin elimination, extending investigation of the drug beyond its current pediatric indication.
This initiative follows recent institution-led studies at Tampa General Hospital and City of Hope that are also exploring PEDMARK’s role in preventing ototoxicity in broader adult cancer populations. Together, these independent trials expand real-world validation of PEDMARK across new tumor types and age groups, potentially supporting wider clinical adoption and future label expansion, which could strengthen Fennec’s position in the oncology supportive care market and benefit patients at high risk of treatment-related hearing loss.
The most recent analyst rating on (TSE:FRX) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is held back primarily by inconsistent profitability and cash flow despite strong gross margins and improving balance-sheet strength. Technicals are also weak (price below key moving averages with negative MACD). Offsetting these, the earnings call points to accelerating sales growth, improved financial flexibility (debt eliminated), and extended exclusivity to 2033, which supports a moderate—but not high—overall score.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., listed on NASDAQ and TSX, is a specialty pharmaceutical company focused on therapies that address chemotherapy-induced side effects. Its lead product, PEDMARK, a sodium thiosulfate injection, is approved in the U.S. to reduce the risk of ototoxicity in pediatric patients receiving cisplatin for localized, non-metastatic solid tumors, and holds a 2A recommendation from the National Comprehensive Cancer Network for adolescent and young adult patients.
Average Trading Volume: 890
Technical Sentiment Signal: Sell
Current Market Cap: C$307.9M
Find detailed analytics on FRX stock on TipRanks’ Stock Analysis page.